Lin Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lin Hu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Yanfei Li
Department of Pharmacy, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University
7 shared publicationsJuanjuan Huang
Department of Pharmacy, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
4 shared publicationsXi Tang
Department of Pharmacy, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University
4 shared publications- Gefei He
Department of Pharmacy, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University)
3 shared publications Qi Huang
Affiliation Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China
3 shared publicationsShiqiong Huang
Department of Pharmacy, the Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, People’s Republic of China
3 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1839608
Voriconazole-associated adverse drug reactions in Chinese patients: incidence, clinical features and the predictive value of ALBI score for hepatotoxicity
Objective: To analyze the incidence, types, and risk factors of adverse drug reactions (ADRs) associated with voriconazole (VRC). Methods: A prospective observational study was conducted at the First Hospital of Changsha from March 1, 2024, to December 31, 2025. Multivariate logistic regression analyses and receiver operating characteristic (ROC) curve analysis were performed to identify risk factors of ADRs. Results: A total of 370 patients were included in the analysis. ADRs occurred in 70 patients (18.9%), while 300 patients (81.1%) experienced no ADRs. The most common ADRs were hepatotoxicity (39/370, 10.5%), neurological disorders (20/370, 5.4%), and visual symptoms (18/370, 4.9%). Most ADRs developed within 4–7 days after treatment initiation (53.6%). Notably, 59 patients (84.3%) discontinued VRC due to ADRs. Among patients with hepatotoxicity, the median trough concentration ( C trough ) was 4.40 mg/L (range, 1.43–10.01 mg/L), which was significantly higher than that in the non-ADR group (3.29 mg/L; range, 0.64–12.80 mg/L; P = 0.016). No significant association was found between VRC C trough and either neurological disorders or visual symptoms. However, patients who experienced visual symptoms received a significantly higher VRC dose (8.00 mg/kg/day; range, 5.00–12.00 mg/kg/day) compared with those without visual symptoms (7.02 mg/kg/day; range, 1.19–13.33 mg/kg/day) ( P = 0.029). Multivariate logistic regression analysis identified VRC C trough and albumin–bilirubin (ALBI) score as significant predictors of hepatotoxicity ( P = 0.033 and P = 0.036, respectively). ROC analysis further indicated that patients with an ALBI score > −2.095 were at increased risk of developing hepatotoxicity. Conclusion: Early monitoring of VRC C trough is essential. In addition to trough levels, the ALBI score demonstrated good predictive value for hepatotoxicity and may represent a promising new approach for predicting hepatotoxicity.
- 10 July 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1839608
Open AccessVoriconazole-associated adverse drug reactions in Chinese patients: incidence, clinical features and the predictive value of ALBI score for hepatotoxicity
Objective: To analyze the incidence, types, and risk factors of adverse drug reactions (ADRs) associated with voriconazole (VRC). Methods: A prospective observational study was conducted at the First Hospital of Changsha from March 1, 2024, to December 31, 2025. Multivariate logistic regression analyses and receiver operating characteristic (ROC) curve analysis were performed to identify risk factors of ADRs. Results: A total of 370 patients were included in the analysis. ADRs occurred in 70 patients (18.9%), while 300 patients (81.1%) experienced no ADRs. The most common ADRs were hepatotoxicity (39/370, 10.5%), neurological disorders (20/370, 5.4%), and visual symptoms (18/370, 4.9%). Most ADRs developed within 4–7 days after treatment initiation (53.6%). Notably, 59 patients (84.3%) discontinued VRC due to ADRs. Among patients with hepatotoxicity, the median trough concentration ( C trough ) was 4.40 mg/L (range, 1.43–10.01 mg/L), which was significantly higher than that in the non-ADR group (3.29 mg/L; range, 0.64–12.80 mg/L; P = 0.016). No significant association was found between VRC C trough and either neurological disorders or visual symptoms. However, patients who experienced visual symptoms received a significantly higher VRC dose (8.00 mg/kg/day; range, 5.00–12.00 mg/kg/day) compared with those without visual symptoms (7.02 mg/kg/day; range, 1.19–13.33 mg/kg/day) ( P = 0.029). Multivariate logistic regression analysis identified VRC C trough and albumin–bilirubin (ALBI) score as significant predictors of hepatotoxicity ( P = 0.033 and P = 0.036, respectively). ROC analysis further indicated that patients with an ALBI score > −2.095 were at increased risk of developing hepatotoxicity. Conclusion: Early monitoring of VRC C trough is essential. In addition to trough levels, the ALBI score demonstrated good predictive value for hepatotoxicity and may represent a promising new approach for predicting hepatotoxicity.
- Open Access
- 19 June 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1837833
Voriconazole therapeutic drug monitoring and safety in HIV-infected patients with invasive fungal disease
Objective: To characterize the distribution of voriconazole (VRC) trough concentrations ( C trough ), identify factors associated with VRC exposure in HIV-infected patients complicated by invasive fungal disease (IFD), and determine the C trough threshold associated with an increased risk of adverse drug reactions (ADRs). Methods: A retrospective study was conducted at the First Hospital of Changsha from 1 January 2021, to 31 December 2025. Univariate and multivariate analyses were performed to identify factors associated with VRC C trough . Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cutoff value for predicting ADRs. Results: A total of 44 patients contributed 55 VRC C trough measurements. The median C trough was 2.44 mg/L (range, 0.07–7.26 mg/L). Of these measurements, 8 (14.5%) were 5.5 mg/L. The interindividual coefficient of variation for C trough was 63.6%. Univariate analysis showed that albumin-bilirubin (ALBI) grade, Child–Pugh classification, hypoalbuminemia, concomitant glucocorticoid use, C-reactive protein levels, and CD4 + /CD8 + ratio were associated with VRC C trough . The mixed-effects model identified ALBI grade, concomitant glucocorticoid use, and the CD4 + /CD8 + ratio as factors significantly associated with VRC C trough . The incidence of ADRs was 20.5% (9/44). Patients who developed ADRs had significantly higher median VRC C trough than those who did not (5.15 mg/L [range, 0.88–5.93 mg/L] vs. 2.40 mg/L [range, 0.07–7.26 mg/L], P = 0.038). ROC analysis yielded an area under the curve (AUC) of 0.720 (95% confidence interval, 0.525–0.914; P = 0.038) for C trough in predicting ADRs. The optimal cutoff value was 4.43 mg/L, with a sensitivity of 66.7% and a specificity of 80.4%. Conclusion: In patients with HIV-infected and IFD, VRC C trough showed substantial variability and was influenced by multiple factors, including ALBI grade, concomitant glucocorticoid use, and the CD4 + /CD8 + ratio. Maintaining VRC C trough < 4.43 mg/L may help reduce the risk of ADRs in this population.
- 19 June 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1837833
Open AccessVoriconazole therapeutic drug monitoring and safety in HIV-infected patients with invasive fungal disease
Objective: To characterize the distribution of voriconazole (VRC) trough concentrations ( C trough ), identify factors associated with VRC exposure in HIV-infected patients complicated by invasive fungal disease (IFD), and determine the C trough threshold associated with an increased risk of adverse drug reactions (ADRs). Methods: A retrospective study was conducted at the First Hospital of Changsha from 1 January 2021, to 31 December 2025. Univariate and multivariate analyses were performed to identify factors associated with VRC C trough . Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cutoff value for predicting ADRs. Results: A total of 44 patients contributed 55 VRC C trough measurements. The median C trough was 2.44 mg/L (range, 0.07–7.26 mg/L). Of these measurements, 8 (14.5%) were 5.5 mg/L. The interindividual coefficient of variation for C trough was 63.6%. Univariate analysis showed that albumin-bilirubin (ALBI) grade, Child–Pugh classification, hypoalbuminemia, concomitant glucocorticoid use, C-reactive protein levels, and CD4 + /CD8 + ratio were associated with VRC C trough . The mixed-effects model identified ALBI grade, concomitant glucocorticoid use, and the CD4 + /CD8 + ratio as factors significantly associated with VRC C trough . The incidence of ADRs was 20.5% (9/44). Patients who developed ADRs had significantly higher median VRC C trough than those who did not (5.15 mg/L [range, 0.88–5.93 mg/L] vs. 2.40 mg/L [range, 0.07–7.26 mg/L], P = 0.038). ROC analysis yielded an area under the curve (AUC) of 0.720 (95% confidence interval, 0.525–0.914; P = 0.038) for C trough in predicting ADRs. The optimal cutoff value was 4.43 mg/L, with a sensitivity of 66.7% and a specificity of 80.4%. Conclusion: In patients with HIV-infected and IFD, VRC C trough showed substantial variability and was influenced by multiple factors, including ALBI grade, concomitant glucocorticoid use, and the CD4 + /CD8 + ratio. Maintaining VRC C trough < 4.43 mg/L may help reduce the risk of ADRs in this population.
- Open Access
- 16 October 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1667461
Personalizing voriconazole dosing in Chinese hematological patients: CYP2C19 phenotype and albumin-bilirubin grade as key predictors of trough concentrations
Purpose: This retrospective, single-center study aimed to evaluate the genetic and non-genetic factors influencing voriconazole (VRC) trough concentration (Ctrough), efficacy and safety in hematological patients.Methods: Medical records of inpatients were reviewed retrospectively. Univariate and multivariate analyses were performed to identify factors contributing to the variability of VRC Ctrough.Results: A total of 375 VRC Ctrough measurements from 89 patients were analyzed. At the time of the initial Ctrough assessment, 74 patients (83.1%) received oral VRC, while 15 patients (16.9%) received intravenous VRC. Among these first Ctrough measurements, 68.5% of patients achieved the target therapeutic range (1.0–5.5 mg/L), whereas 28.1% had subtherapeutic concentrations and 3.4% had supratherapeutic concentrations. The dose-normalized VRC Ctrough (Ctrough/D) were significantly higher in poor metabolizers (PMs) compared to normal metabolizers (NMs) (P = 0.001) and intermediate metabolizers (IMs) (P = 0.021). The albumin-bilirubin (ALBI) grade, a novel liver function assessment tool, was significantly associated with VRC Ctrough/D. Patients with ALBI grade 3 had significantly higher Ctrough/D values compared to those with grade 2 (P = 0.001) and grade 1 (P < 0.001). The linear mixed model revealed that sex, concomitant glucocorticoid use, creatinine clearance rate (Ccr), CYP2C19 genotype, and ALBI grade were statistically significant predictors of VRC Ctrough/D. A total of 10 patients (11.2%) had their VRC dosage adjusted based on therapeutic drug monitoring (TDM). The overall treatment success rate was 75.3% (67/89). Adverse drug reactions (ADRs) were observed in 12 patients (13.5%) during VRC therapy.Conclusion: CYP2C19 phenotype, ALBI grade, sex, Ccr and concomitant use of glucocorticoids contribute to the variability of VRC Ctrough and should be comprehensively considered when determining VRC dosage in Chinese hematological patients.
- 16 October 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1667461
Open AccessPersonalizing voriconazole dosing in Chinese hematological patients: CYP2C19 phenotype and albumin-bilirubin grade as key predictors of trough concentrations
Purpose: This retrospective, single-center study aimed to evaluate the genetic and non-genetic factors influencing voriconazole (VRC) trough concentration (Ctrough), efficacy and safety in hematological patients.Methods: Medical records of inpatients were reviewed retrospectively. Univariate and multivariate analyses were performed to identify factors contributing to the variability of VRC Ctrough.Results: A total of 375 VRC Ctrough measurements from 89 patients were analyzed. At the time of the initial Ctrough assessment, 74 patients (83.1%) received oral VRC, while 15 patients (16.9%) received intravenous VRC. Among these first Ctrough measurements, 68.5% of patients achieved the target therapeutic range (1.0–5.5 mg/L), whereas 28.1% had subtherapeutic concentrations and 3.4% had supratherapeutic concentrations. The dose-normalized VRC Ctrough (Ctrough/D) were significantly higher in poor metabolizers (PMs) compared to normal metabolizers (NMs) (P = 0.001) and intermediate metabolizers (IMs) (P = 0.021). The albumin-bilirubin (ALBI) grade, a novel liver function assessment tool, was significantly associated with VRC Ctrough/D. Patients with ALBI grade 3 had significantly higher Ctrough/D values compared to those with grade 2 (P = 0.001) and grade 1 (P < 0.001). The linear mixed model revealed that sex, concomitant glucocorticoid use, creatinine clearance rate (Ccr), CYP2C19 genotype, and ALBI grade were statistically significant predictors of VRC Ctrough/D. A total of 10 patients (11.2%) had their VRC dosage adjusted based on therapeutic drug monitoring (TDM). The overall treatment success rate was 75.3% (67/89). Adverse drug reactions (ADRs) were observed in 12 patients (13.5%) during VRC therapy.Conclusion: CYP2C19 phenotype, ALBI grade, sex, Ccr and concomitant use of glucocorticoids contribute to the variability of VRC Ctrough and should be comprehensively considered when determining VRC dosage in Chinese hematological patients.
- Open Access
- 1 October 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 9265-9278
A Systematic Review of Population Pharmacokinetics, Safety, and Factors Influencing Trough Concentrations of Voriconazole in Asian Patients with Liver Dysfunction
Objective: This study systematically reviews recent research on voriconazole (VRC) use in Asian patients with liver dysfunction to provide a scientific basis for individualized therapy. Methods: A comprehensive literature search was conducted in EMBASE, PubMed, Web of Science, and the Cochrane Library for clinical studies on VRC use in Asian patients with liver dysfunction, published between January 1, 2000, and March 1, 2025. Studies meeting the inclusion and exclusion criteria were analyzed to summarize VRC safety, factors influencing trough concentrations (Ctrough), pharmacokinetic characteristics, and advancements in dose optimization. Results: A total of 14 studies were included, comprising 9 studies on the safety of VRC in patients with liver dysfunction, 5 studies investigating factors affecting VRC Ctrough, and 6 studies on population pharmacokinetics (PPK) in this population. The most commonly reported adverse drug reactions (ADRs) related to VRC were hepatotoxicity, neurotoxicity, and visual impairment. ADRs typically occurred within 7 days of VRC administration. VRC Ctrough are influenced by several factors, including liver impairment severity, CYP2C19 polymorphisms, and albumin and bilirubin levels. The PPK models assessed clearance (CL) in patients with different Child-Pugh (CP) classifications, all of which showed a significant reduction in CL among CP-C patients. Regarding the elimination half-life (t₁/2), CP-C patients exhibited a significant prolongation. Conclusion: Therapeutic drug monitoring (TDM) and PPK studies can aid in optimizing VRC dosing, ensuring safer and more effective individualized therapy.
- 1 October 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 9265-9278
Open AccessA Systematic Review of Population Pharmacokinetics, Safety, and Factors Influencing Trough Concentrations of Voriconazole in Asian Patients with Liver Dysfunction
Objective: This study systematically reviews recent research on voriconazole (VRC) use in Asian patients with liver dysfunction to provide a scientific basis for individualized therapy. Methods: A comprehensive literature search was conducted in EMBASE, PubMed, Web of Science, and the Cochrane Library for clinical studies on VRC use in Asian patients with liver dysfunction, published between January 1, 2000, and March 1, 2025. Studies meeting the inclusion and exclusion criteria were analyzed to summarize VRC safety, factors influencing trough concentrations (Ctrough), pharmacokinetic characteristics, and advancements in dose optimization. Results: A total of 14 studies were included, comprising 9 studies on the safety of VRC in patients with liver dysfunction, 5 studies investigating factors affecting VRC Ctrough, and 6 studies on population pharmacokinetics (PPK) in this population. The most commonly reported adverse drug reactions (ADRs) related to VRC were hepatotoxicity, neurotoxicity, and visual impairment. ADRs typically occurred within 7 days of VRC administration. VRC Ctrough are influenced by several factors, including liver impairment severity, CYP2C19 polymorphisms, and albumin and bilirubin levels. The PPK models assessed clearance (CL) in patients with different Child-Pugh (CP) classifications, all of which showed a significant reduction in CL among CP-C patients. Regarding the elimination half-life (t₁/2), CP-C patients exhibited a significant prolongation. Conclusion: Therapeutic drug monitoring (TDM) and PPK studies can aid in optimizing VRC dosing, ensuring safer and more effective individualized therapy.
- Open Access
- 11 July 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1628032
Efficacy and safety of vitamin E as adjunctive therapy for epilepsy: a systematic review and meta-analysis of randomized control trials
Objective: Vitamin E, functioning as an antioxidant, holds substantial potential in the adjuvant treatment of epilepsy. However, it remains uncertain whether the existing evidence is adequate to validate the use of vitamin E as an add-on therapy for improving epilepsy outcomes. The aim of this study was to explore the efficacy and safety of vitamin E as an adjuvant treatment for epilepsy.Methods: We searched PubMed, Embase, the Cochrane Library, and Chinese databases including the Chinese Biomedicine Literature Database, China National Knowledge Infrastructure, Chinese Sci-tech Journal Database, Wanfang Data for eligible studies from inception to February 28, 2025. Meta-analysis was performed to calculate the risk ratio (RR) and weighted mean difference (WMD) of the included randomized controlled trials (RCTs).Results: Among the 2,348 records obtained, 11 RCTs involving 824 patients were included after literature screening. Vitamin E had a potential advantage in reducing seizure frequency by >75% (RR = 1.73, 95% confidence interval (CI) (1.31, 2.28), p < 0.01), compared with the control group. Subgroup analysis showed a statistically significant difference in the reduction of seizure frequency by >50% (RR = 1.58, 95% CI (1.27, 1.96), p < 0.01) between the vitamin E group and the control group, especially in children (RR = 1.69, 95% CI (1.29, 2.20), p < 0.01). The plasma total antioxidant capacity was higher (WMD = 3.03, 95% CI (2.65, 3.40), p < 0.01) while the malondialdehyde levels were lower (WMD = −6.28, 95% CI (−8.01, −4.54), p < 0.01) in the vitamin E group than in the control group. There was no statistically significant difference in the rates of total adverse events (RR = 0.97, 95% CI (0.93, 1.02), p = 0.25).Conclusion: Vitamin E shows potential as adjunctive therapy, particularly in pediatric populations, with acceptable safety profile, but high-quality trials are required to confirm its efficacy and safety.
- 11 July 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1628032
Open AccessEfficacy and safety of vitamin E as adjunctive therapy for epilepsy: a systematic review and meta-analysis of randomized control trials
Objective: Vitamin E, functioning as an antioxidant, holds substantial potential in the adjuvant treatment of epilepsy. However, it remains uncertain whether the existing evidence is adequate to validate the use of vitamin E as an add-on therapy for improving epilepsy outcomes. The aim of this study was to explore the efficacy and safety of vitamin E as an adjuvant treatment for epilepsy.Methods: We searched PubMed, Embase, the Cochrane Library, and Chinese databases including the Chinese Biomedicine Literature Database, China National Knowledge Infrastructure, Chinese Sci-tech Journal Database, Wanfang Data for eligible studies from inception to February 28, 2025. Meta-analysis was performed to calculate the risk ratio (RR) and weighted mean difference (WMD) of the included randomized controlled trials (RCTs).Results: Among the 2,348 records obtained, 11 RCTs involving 824 patients were included after literature screening. Vitamin E had a potential advantage in reducing seizure frequency by >75% (RR = 1.73, 95% confidence interval (CI) (1.31, 2.28), p < 0.01), compared with the control group. Subgroup analysis showed a statistically significant difference in the reduction of seizure frequency by >50% (RR = 1.58, 95% CI (1.27, 1.96), p < 0.01) between the vitamin E group and the control group, especially in children (RR = 1.69, 95% CI (1.29, 2.20), p < 0.01). The plasma total antioxidant capacity was higher (WMD = 3.03, 95% CI (2.65, 3.40), p < 0.01) while the malondialdehyde levels were lower (WMD = −6.28, 95% CI (−8.01, −4.54), p < 0.01) in the vitamin E group than in the control group. There was no statistically significant difference in the rates of total adverse events (RR = 0.97, 95% CI (0.93, 1.02), p = 0.25).Conclusion: Vitamin E shows potential as adjunctive therapy, particularly in pediatric populations, with acceptable safety profile, but high-quality trials are required to confirm its efficacy and safety.
- 6 November 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (11) , e0112624
Therapeutic drug monitoring and safety of voriconazole in patients with liver dysfunction
This study aims to describe the distribution characteristics of voriconazole (VRC) plasma trough concentrations ( C trough ) in patients with liver dysfunction, identify factors influencing VRC C trough , and provide recommendations for the use of VRC in this population. We retrospectively collected medical records of hospitalized patients with liver dysfunction who used VRC and underwent therapeutic drug monitoring (TDM) at the First Hospital of Changsha. The severity of liver dysfunction was assessed by the Child–Pugh (CP) score. Multiple linear regression was employed to explore factors affecting VRC C trough in these patients. A total of 147 C trough from 102 patients with liver dysfunction were analyzed. Patients were categorized into a control group ( n = 40), CP-A ( n = 39), CP-B ( n = 11), and CP-C group ( n = 12). The initial probability of target attainment of C trough was 70.6%, with 6.9% of patients obtaining subtherapeutic C trough and 22.5% obtaining supertherapeutic C trough . The initial C trough in CP-A and B were 5.05 (0.64–9.57) mg/L and 5.37 (0.26–10.01) mg/L, respectively, significantly higher than the control group ( P = 0.021 and P = 0.010). The proportion of VRC C trough of >5.5 mg/L in CP-A and B was 33.3% and 45.5%, respectively. Multiple linear regression analysis revealed that factors such as age ≥70 years, CP class, C-reactive protein (CRP), and direct bilirubin were significantly related to the initial VRC C trough . Among all measurements, patients with severe inflammation (CRP >100 mg/L), aged ≥70 years, and albumin levels of C trough . The treatment success rate of VRC was 69.6% (71 of 102), and the rate of VRC-related adverse drug reactions was 29.4% (30 of 102). The recommended half-maintenance dose may lead to elevated VRC C trough in patients with CP-A and CP-B. TDM is essential for patients with advanced age, severe infections, or hypoalbuminemia to prevent excessive VRC trough levels.
- 6 November 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (11) , e0112624
Therapeutic drug monitoring and safety of voriconazole in patients with liver dysfunction
This study aims to describe the distribution characteristics of voriconazole (VRC) plasma trough concentrations ( C trough ) in patients with liver dysfunction, identify factors influencing VRC C trough , and provide recommendations for the use of VRC in this population. We retrospectively collected medical records of hospitalized patients with liver dysfunction who used VRC and underwent therapeutic drug monitoring (TDM) at the First Hospital of Changsha. The severity of liver dysfunction was assessed by the Child–Pugh (CP) score. Multiple linear regression was employed to explore factors affecting VRC C trough in these patients. A total of 147 C trough from 102 patients with liver dysfunction were analyzed. Patients were categorized into a control group ( n = 40), CP-A ( n = 39), CP-B ( n = 11), and CP-C group ( n = 12). The initial probability of target attainment of C trough was 70.6%, with 6.9% of patients obtaining subtherapeutic C trough and 22.5% obtaining supertherapeutic C trough . The initial C trough in CP-A and B were 5.05 (0.64–9.57) mg/L and 5.37 (0.26–10.01) mg/L, respectively, significantly higher than the control group ( P = 0.021 and P = 0.010). The proportion of VRC C trough of >5.5 mg/L in CP-A and B was 33.3% and 45.5%, respectively. Multiple linear regression analysis revealed that factors such as age ≥70 years, CP class, C-reactive protein (CRP), and direct bilirubin were significantly related to the initial VRC C trough . Among all measurements, patients with severe inflammation (CRP >100 mg/L), aged ≥70 years, and albumin levels of C trough . The treatment success rate of VRC was 69.6% (71 of 102), and the rate of VRC-related adverse drug reactions was 29.4% (30 of 102). The recommended half-maintenance dose may lead to elevated VRC C trough in patients with CP-A and CP-B. TDM is essential for patients with advanced age, severe infections, or hypoalbuminemia to prevent excessive VRC trough levels.
- Open Access
- 9 June 2024
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 50 (1) , 1-12
Clinical application of voriconazole in pediatric patients: a systematic review
The purpose of this study was to review the literature on the clinical use of voriconazole (VRC) in pediatric patients. MEDLINE, Embase, PubMed, Web of Science, and Cochrane Library were searched from January 1, 2000, to August 15, 2023 for relevant clinical studies on VRC use in pediatric patients. Data were collected based on inclusion and exclusion criteria, and a systematic review was performed on recent research related to the use of VRC in pediatric patients. This systematic review included a total of 35 observational studies among which there were 16 studies investigating factors influencing VRC plasma trough concentrations (Ctrough) in pediatric patients, 14 studies exploring VRC maintenance doses required to achieve target range of Ctrough, and 11 studies focusing on population pharmacokinetic (PPK) research of VRC in pediatric patients. Our study found that the Ctrough of VRC were influenced by both genetic and non-genetic factors. The optimal dosing of VRC was correlated with age in pediatric patients, and younger children usually required higher VRC doses to achieve target Ctrough compared to older children. Establishing a PPK model for VRC can assist in achieving more precise individualized dosing in children.
- 9 June 2024
- Published by Springer Nature in Italian Journal of Pediatrics
- Vol. 50 (1) , 1-12
Open AccessClinical application of voriconazole in pediatric patients: a systematic review
The purpose of this study was to review the literature on the clinical use of voriconazole (VRC) in pediatric patients. MEDLINE, Embase, PubMed, Web of Science, and Cochrane Library were searched from January 1, 2000, to August 15, 2023 for relevant clinical studies on VRC use in pediatric patients. Data were collected based on inclusion and exclusion criteria, and a systematic review was performed on recent research related to the use of VRC in pediatric patients. This systematic review included a total of 35 observational studies among which there were 16 studies investigating factors influencing VRC plasma trough concentrations (Ctrough) in pediatric patients, 14 studies exploring VRC maintenance doses required to achieve target range of Ctrough, and 11 studies focusing on population pharmacokinetic (PPK) research of VRC in pediatric patients. Our study found that the Ctrough of VRC were influenced by both genetic and non-genetic factors. The optimal dosing of VRC was correlated with age in pediatric patients, and younger children usually required higher VRC doses to achieve target Ctrough compared to older children. Establishing a PPK model for VRC can assist in achieving more precise individualized dosing in children.
- Open Access
- 11 September 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (9) , e0288794
Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients
The aim of this study was to evaluate factors that impact on voriconazole (VRC) population pharmacokinetic (PPK) parameters and explore the optimal dosing regimen for different CYP2C19 genotypes in Chinese paediatric patients. PPK analysis was used to identify the factors contributing to the variability in VRC plasma trough concentrations. A total of 210 VRC trough concentrations from 91 paediatric patients were included in the study. The median VRC trough concentration was 1.23 mg/L (range, 0.02 to 8.58 mg/L). At the measurement of all the trough concentrations, the target range (1.0~5.5 mg/L) was achieved in 52.9% of the patients, while subtherapeutic and supratherapeutic concentrations were obtained in 40.9% and 6.2% of patients, respectively. VRC trough concentrations were adjusted for dose (Ctrough/D), with normal metabolizers (NMs) and intermediate metabolizers (IMs) having significantly lower levels than poor metabolizers (PMs) (PN-P < 0.001, PI-P = 0.039). A one-compartment model with first-order absorption and elimination was suitable to describe the VRC pharmacokinetic characteristics. The final model of VRC PPK analysis contained CYP2C19 phenotype as a significant covariate for clearance. Dose simulations suggested that a maintenance dose of 9 mg/kg orally or 8 mg/kg intravenously twice daily was appropriate for NMs to achieve the target concentration. A maintenance dose of 9 mg/kg orally or 5 mg/kg intravenously twice daily was appropriate for IMs. Meanwhile, PMs could use lower maintenance dose and an oral dose of 6 mg/kg twice daily or an intravenous dose of 5mg/kg twice daily was appropriate. To increase the probability of achieving the therapeutic range and improving efficacy, CYP2C19 phenotype can be used to predict VRC trough concentrations and guide dose adjustments in Chinese pediatric patients.
- 11 September 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (9) , e0288794
Open AccessPopulation pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients
The aim of this study was to evaluate factors that impact on voriconazole (VRC) population pharmacokinetic (PPK) parameters and explore the optimal dosing regimen for different CYP2C19 genotypes in Chinese paediatric patients. PPK analysis was used to identify the factors contributing to the variability in VRC plasma trough concentrations. A total of 210 VRC trough concentrations from 91 paediatric patients were included in the study. The median VRC trough concentration was 1.23 mg/L (range, 0.02 to 8.58 mg/L). At the measurement of all the trough concentrations, the target range (1.0~5.5 mg/L) was achieved in 52.9% of the patients, while subtherapeutic and supratherapeutic concentrations were obtained in 40.9% and 6.2% of patients, respectively. VRC trough concentrations were adjusted for dose (Ctrough/D), with normal metabolizers (NMs) and intermediate metabolizers (IMs) having significantly lower levels than poor metabolizers (PMs) (PN-P < 0.001, PI-P = 0.039). A one-compartment model with first-order absorption and elimination was suitable to describe the VRC pharmacokinetic characteristics. The final model of VRC PPK analysis contained CYP2C19 phenotype as a significant covariate for clearance. Dose simulations suggested that a maintenance dose of 9 mg/kg orally or 8 mg/kg intravenously twice daily was appropriate for NMs to achieve the target concentration. A maintenance dose of 9 mg/kg orally or 5 mg/kg intravenously twice daily was appropriate for IMs. Meanwhile, PMs could use lower maintenance dose and an oral dose of 6 mg/kg twice daily or an intravenous dose of 5mg/kg twice daily was appropriate. To increase the probability of achieving the therapeutic range and improving efficacy, CYP2C19 phenotype can be used to predict VRC trough concentrations and guide dose adjustments in Chinese pediatric patients.
- 17 July 2023
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 79 (9) , 1271-1278
Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients
Purpose The objective of this study was to evaluate factors influencing voriconazole (VRC) plasma trough concentrations and provide research data for optimizing VRC dosing in Chinese paediatric patients. Methods Medical records of inpatients were reviewed retrospectively. Multivariate linear regression analysis was used to identify the factors contributing to the variability of VRC plasma trough concentrations. Results A total of 250 VRC plasma trough concentrations from 131 paediatric patients were included in the analysis. The median VRC plasma trough concentration was 1.28 mg·L−1 (range, 0.02 to 9.69 mg·L−1). The target range was achieved in 51.6% of patients, while subtherapeutic and supratherapeutic concentrations were obtained in 40.4% and 8.0% of paediatric patients, respectively. The most commonly identified cytochrome P450 2C19 (CYP2C19) phenotype was intermediate metabolizers (IMs) (48.9%), followed by normal metabolizers (NMs) (40.5%) and poor metabolizers (PMs) (10.7%), but no ultrarapid metabolizers (UMs) were observed in our study. VRC plasma trough concentrations adjusted for dose (Cmin/D) were significantly lower in both NMs and IMs compared to PMs (PN-P < 0.001 and PI-P = 0.010, respectively). The dosage of VRC required to achieve the therapeutic range was related to age, with children aged < 6 years needing a significantly higher oral dose of VRC. The oral and intravenous maintenance doses needed to reach the therapeutic range were significantly lower than the recommended maintenance dose (P < 0.001, P < 0.001). Factors such as CYP2C19 polymorphisms, the combination of omeprazole, levels of albumin and alanine aminotransferase, were found to affect VRC exposure and explained some of the variability. Conclusions The VRC plasma trough concentration is significantly influenced by the CYP2C19 phenotype. The recommended maintenance dose for pediatric patients may not be appropriate for Chinese patients. To increase the probability of achieving the therapeutic range for VRC plasma trough concentration, the administration of VRC should consider the age of paediatric patients and the presence of CYP2C19 polymorphisms.
- 17 July 2023
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 79 (9) , 1271-1278
Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients
Purpose The objective of this study was to evaluate factors influencing voriconazole (VRC) plasma trough concentrations and provide research data for optimizing VRC dosing in Chinese paediatric patients. Methods Medical records of inpatients were reviewed retrospectively. Multivariate linear regression analysis was used to identify the factors contributing to the variability of VRC plasma trough concentrations. Results A total of 250 VRC plasma trough concentrations from 131 paediatric patients were included in the analysis. The median VRC plasma trough concentration was 1.28 mg·L−1 (range, 0.02 to 9.69 mg·L−1). The target range was achieved in 51.6% of patients, while subtherapeutic and supratherapeutic concentrations were obtained in 40.4% and 8.0% of paediatric patients, respectively. The most commonly identified cytochrome P450 2C19 (CYP2C19) phenotype was intermediate metabolizers (IMs) (48.9%), followed by normal metabolizers (NMs) (40.5%) and poor metabolizers (PMs) (10.7%), but no ultrarapid metabolizers (UMs) were observed in our study. VRC plasma trough concentrations adjusted for dose (Cmin/D) were significantly lower in both NMs and IMs compared to PMs (PN-P < 0.001 and PI-P = 0.010, respectively). The dosage of VRC required to achieve the therapeutic range was related to age, with children aged < 6 years needing a significantly higher oral dose of VRC. The oral and intravenous maintenance doses needed to reach the therapeutic range were significantly lower than the recommended maintenance dose (P < 0.001, P < 0.001). Factors such as CYP2C19 polymorphisms, the combination of omeprazole, levels of albumin and alanine aminotransferase, were found to affect VRC exposure and explained some of the variability. Conclusions The VRC plasma trough concentration is significantly influenced by the CYP2C19 phenotype. The recommended maintenance dose for pediatric patients may not be appropriate for Chinese patients. To increase the probability of achieving the therapeutic range for VRC plasma trough concentration, the administration of VRC should consider the age of paediatric patients and the presence of CYP2C19 polymorphisms.
- Open Access
- 21 November 2022
- Published by Springer Nature in Research Square
Population pharmacokinetics of voriconazole and CYP2C19 phenotype for dose optimization in hematological patients with invasive fungal infections
Aims The aim of this study was to evaluate factors that impact on voriconazole trough concentration and explore the optimal dosing regimen of voriconazole for different CYP2C19 genotypes in a Chinese population. Methods Medical records of inpatients were reviewed retrospectively. Multivariate linear regression and population pharmacokinetic analysis was used to identify the factors contributing to the variability of voriconazole trough concentrations. Results A total of 363 voriconazole trough concentrations from 89 patients were included, with high inter- and intraindividual variability. At the measurement of the first trough concentration, the target range (1.0–5.5 mg·L− 1) was achieved in 68.5% of patients, while subtherapeutic and supratherapeutic concentrations were obtained in 28.1% and 3.4% of patients, respectively. In our study, the most commonly identified cytochrome P450 2C19 (CYP2C19) phenotype was normal metabolizers (NMs) (46.1%), followed by intermediate metabolizers (IMs) (40.4%) and poor metabolizers (PMs) (13.5%). Initial trough concentrations were adjusted for dose, with NMs and IMs were both significantly lower than PMs (PN−P=0.010 and PI−P=0.048, respectively). The median intravenous maintenance dose to reach a therapeutic range was significantly lower than the recommended intravenous maintenance dose (P = 0.009). Affecting factors in our study such as age, administration routes, CYP2C19 polymorphisms and aspartate transaminase (AST) explained 41.4% of the variability in voriconazole exposure. The final model of voriconazole population pharmacokinetic analysis contained age as a significant covariate for the distribution volume and CYP2C19 phenotype as a significant covariate for the clearance rate. Dose simulations indicated that 300, 250, 150 mg orally twice daily is appropriate for NMs, IMs and PMs to achieve target range, respectively. Conclusions To increase the probability of achieving the therapeutic range and improving efficacy, CYP2C19 phenotype can be used to predict voriconazole trough concentrations and guide dose adjustment.
- 21 November 2022
- Published by Springer Nature in Research Square
Open AccessPopulation pharmacokinetics of voriconazole and CYP2C19 phenotype for dose optimization in hematological patients with invasive fungal infections
Aims The aim of this study was to evaluate factors that impact on voriconazole trough concentration and explore the optimal dosing regimen of voriconazole for different CYP2C19 genotypes in a Chinese population. Methods Medical records of inpatients were reviewed retrospectively. Multivariate linear regression and population pharmacokinetic analysis was used to identify the factors contributing to the variability of voriconazole trough concentrations. Results A total of 363 voriconazole trough concentrations from 89 patients were included, with high inter- and intraindividual variability. At the measurement of the first trough concentration, the target range (1.0–5.5 mg·L− 1) was achieved in 68.5% of patients, while subtherapeutic and supratherapeutic concentrations were obtained in 28.1% and 3.4% of patients, respectively. In our study, the most commonly identified cytochrome P450 2C19 (CYP2C19) phenotype was normal metabolizers (NMs) (46.1%), followed by intermediate metabolizers (IMs) (40.4%) and poor metabolizers (PMs) (13.5%). Initial trough concentrations were adjusted for dose, with NMs and IMs were both significantly lower than PMs (PN−P=0.010 and PI−P=0.048, respectively). The median intravenous maintenance dose to reach a therapeutic range was significantly lower than the recommended intravenous maintenance dose (P = 0.009). Affecting factors in our study such as age, administration routes, CYP2C19 polymorphisms and aspartate transaminase (AST) explained 41.4% of the variability in voriconazole exposure. The final model of voriconazole population pharmacokinetic analysis contained age as a significant covariate for the distribution volume and CYP2C19 phenotype as a significant covariate for the clearance rate. Dose simulations indicated that 300, 250, 150 mg orally twice daily is appropriate for NMs, IMs and PMs to achieve target range, respectively. Conclusions To increase the probability of achieving the therapeutic range and improving efficacy, CYP2C19 phenotype can be used to predict voriconazole trough concentrations and guide dose adjustment.